Correction to: Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.
作者信息
Marofi Faroogh, Tahmasebi Safa, Rahman Heshu Sulaiman, Kaigorodov Denis, Markov Alexander, Yumashev Alexei Valerievich, Shomali Navid, Chartrand Max Stanley, Pathak Yashwant, Mohammed Rebar N, Jarahian Mostafa, Motavalli Roza, Khiavi Farhad Motavalli
机构信息
Department of Hematology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Department of Immunology, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
出版信息
Stem Cell Res Ther. 2021 Aug 6;12(1):443. doi: 10.1186/s13287-021-02523-2.
Abstract
摘要
相似文献
1
Correction to: Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.对以下内容的修正：离多发性骨髓瘤的成功治疗更近一步了吗？嵌合抗原受体T细胞是一个令人乐观的充分理由。
Stem Cell Res Ther. 2021 Aug 6;12(1):443. doi: 10.1186/s13287-021-02523-2.
2
Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.多发性骨髓瘤的成功治疗是否更近了一步？CAR-T 细胞是一个值得乐观的好理由。
Stem Cell Res Ther. 2021 Mar 29;12(1):217. doi: 10.1186/s13287-021-02283-z.
3
Chimeric antigen receptor T-cell therapy for multiple myeloma.嵌合抗原受体 T 细胞疗法治疗多发性骨髓瘤。
Int J Hematol. 2020 Apr;111(4):530-534. doi: 10.1007/s12185-020-02827-8. Epub 2020 Jan 25.
4
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.复发或难治性多发性骨髓瘤患者中人性化抗CD19和抗BCMA嵌合抗原受体T细胞的联合应用：一项单臂2期试验
Lancet Haematol. 2019 Oct;6(10):e521-e529. doi: 10.1016/S2352-3026(19)30115-2. Epub 2019 Aug 1.
5
CAR-T treatment for hematological malignancies.嵌合抗原受体T细胞（CAR-T）疗法治疗血液系统恶性肿瘤。
J Investig Med. 2020 Jun;68(5):956-964. doi: 10.1136/jim-2020-001290. Epub 2020 Mar 21.
6
Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.COVID-19 感染后复发/难治性多发性骨髓瘤患者抗 BCMA CAR T 治疗：1 例报告。
J Med Case Rep. 2021 Feb 19;15(1):90. doi: 10.1186/s13256-020-02598-0.
7
[Clinical development of CAR-T therapy for refractory multiple myeloma].[嵌合抗原受体T细胞疗法治疗难治性多发性骨髓瘤的临床进展]
Rinsho Ketsueki. 2018;59(8):1058-1065. doi: 10.11406/rinketsu.59.1058.
8
Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy.为多发性骨髓瘤的成功治疗铺平道路：嵌合抗原受体 T 细胞疗法。
Cells. 2020 Apr 16;9(4):983. doi: 10.3390/cells9040983.
9
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma.一项针对复发或难治性多发性骨髓瘤患者的靶向 B 细胞成熟抗原嵌合抗原受体 T 细胞疗法 LCAR-B38M 的 1 期、开放性研究。
J Hematol Oncol. 2018 Dec 20;11(1):141. doi: 10.1186/s13045-018-0681-6.
10
Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma.BCMA CAR-T 细胞疗法在多发性骨髓瘤中的安全性和临床疗效。
J Hematol Oncol. 2020 Dec 3;13(1):164. doi: 10.1186/s13045-020-01001-1.
引用本文的文献
1
Exosomal peptides and proteins in wound healing and skin regeneration.伤口愈合与皮肤再生中的外泌体肽和蛋白质
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul 8. doi: 10.1007/s00210-025-04426-y.
2
Potential of chimeric antigen receptor (CAR)-redirected immune cells in breast cancer therapies: Recent advances.嵌合抗原受体（CAR）靶向免疫细胞在乳腺癌治疗中的潜力：最新进展。
J Cell Mol Med. 2022 Aug;26(15):4137-4156. doi: 10.1111/jcmm.17465. Epub 2022 Jun 28.
3
CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool.CRISPR/Cas9 在癌症治疗中的应用：一种开拓性的基因组编辑工具。
Cell Mol Biol Lett. 2022 May 4;27(1):35. doi: 10.1186/s11658-022-00336-6.
本文引用的文献
1
Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.多发性骨髓瘤的成功治疗是否更近了一步？CAR-T 细胞是一个值得乐观的好理由。
Stem Cell Res Ther. 2021 Mar 29;12(1):217. doi: 10.1186/s13287-021-02283-z.
Zotero 插件